Key Highlights
- NVS shares traded up 6.16% intraday to $161.43, extending gains from a $152.06 prior close.
- Phase III REMODEL-1 and REMODEL-2 trials showed remibrutinib outperformed an older treatment in reducing relapse rates in multiple sclerosis patients.
- The company separately paused eight Clinical Trials of an experimental CAR-T therapy after three patient deaths from severe immune reactions.
- Remibrutinib is already approved for two chronic inflammatory skin conditions and generated $64 million in second-quarter sales.
Positive Multiple Sclerosis Data Drives Today's Rally
Novartis (NYSE:NVS) shares rose sharply after the company announced that its oral drug remibrutinib outperformed an older treatment in reducing relapses in patients with a form of multiple sclerosis, boosting hopes the medicine could become a blockbuster product. The results mark the first success from three closely watched Novartis pipeline programs due to deliver data this year.
The two late-stage trials, REMODEL-1 and REMODEL-2, compared remibrutinib with an existing approved multiple sclerosis therapy in adult patients, showing both strong relapse prevention and clinically meaningful results in slowing disability progression.
Analysts See a Best-in-Class Profile Emerging
One research firm's analyst described the drug as looking like at least a best-in-class oral agent, noting that the combination of strong relapse prevention and an improved liver safety profile made remibrutinib a compelling choice relative to rival treatments in its class. Novartis is seeking to replenish its drug pipeline as it faces Revenue pressure from generic competition to a blockbuster heart-failure drug.
Investors Look Past CAR-T Safety Pause
Shares rose even as investors largely shrugged off separate news that Novartis had paused eight clinical trials of an experimental CAR-T therapy for autoimmune disorders after three patient deaths from severe immune reactions, with the market instead focusing on the strong multiple sclerosis data. Novartis carries a market Capitalization of roughly $306.83 billion.
Multiple Indications Could Expand the Drug's Commercial Potential
Remibrutinib is already approved for two chronic inflammatory skin conditions that cause severe hives, generating $64 million in second-quarter sales under its existing brand. Novartis is also testing the drug for another skin disease and food allergies, with some analysts estimating peak annual sales could reach as much as $9 billion across all indications if development continues to succeed.
Regulatory Filings and Safety Data Will Be Key Catalysts Ahead
Novartis plans to seek regulatory approvals globally for remibrutinib in multiple sclerosis and will present full trial data at an upcoming medical conference. Investors will also want more detailed safety data following the two patient deaths in the multiple sclerosis trials, which were not linked to treatment, alongside further updates on the paused CAR-T program.



_11_19_2026_18_10_09_455845.jpg)

_11_19_2026_18_15_38_890267.jpg)
Please wait processing your request...